Preliminary Assessment of [18F]BL40 in PET/CT Scans

CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease. This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans: 18F-BL40 and 18F-FDG as part of this study.

Inclusion Criteria: 1. Age ≥19 years 2. Life expectancy ≥3 months 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 4. Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers: * Diffuse large B-Cell lymphoma * Multiple myeloma * Mantle cell lymphoma * Marginal zone lymphoma * Chronic lymphocytic leukemia/small cell lymphoma * Waldenström Macroglobulinemia Exclusion Criteria: 1. Pregnant or breast-feeding 2. Medically unstable (e.g., acute illness, unstable vital signs) 3. Unable to lie supine for the duration of imaging 4. Unable to provide written consent 5. Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm) 6. Participants with a history of uncontrolled allergic reactions and/or known or expected hypersensitivity to the peptide diagnostic \[18F\]BL40 or any of its excipients.